LONDON, Nov. 15, 2017 /PRNewswire/ -- General Report Contents
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
Download the full report: https://www.reportbuyer.com/product/5175233
In moderate to severe cases the treatment involves disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (Rheumatrex®). Steroid injections into the joint or tendon may be helpful in some cases. Another option includes biologics, such as HUMIRA® (adalimumab), Amjevita™ and Imraldi® (biosimilars to HUMIRA®), CIMZIA® (certolizumab pegol), Enbrel® (etanercept), Erelzi® and Benepali® (biosimilars to Enbrel®), SIMPONI® (golimumab), REMICADE® (infliximab), Inflectra® and Flixabi (biosimilars to REMICADE®), Renflexis® (infliximab-abda) and Cosentyx® (secukinumab). Some of these DMARDs may be used for the treatment of ankylosing spondylitis as well as for other immune disorders, such as psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and others.
AbstractAnkylosing spondylitis (AS) is a form of arthritis, primarily affecting the spine. AS causes an inflammation in vertebrae and can lead to severe chronic pain and significantly decreases the quality of life. In severe cases the disease can lead to ankylosis -- new bone formation in the spine, causing the spine to fuse in a fixed, immobile position. AS can also affect joints and cause inflammation in shoulders, hips, ribs, heels and others. Sometimes the disease may involve even other organs such as eyes (known as iritis or uveitis) or lungs and heart.
Scope2014-2024
Download the full report: https://www.reportbuyer.com/product/5175233
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
- Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
Download the full report: https://www.reportbuyer.com/product/5175233
Advertisement
- Market Drivers & Limiters for each chapter segment
- Competitive Analysis for each chapter segment
- Section on recent mergers & acquisitions
In moderate to severe cases the treatment involves disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (Rheumatrex®). Steroid injections into the joint or tendon may be helpful in some cases. Another option includes biologics, such as HUMIRA® (adalimumab), Amjevita™ and Imraldi® (biosimilars to HUMIRA®), CIMZIA® (certolizumab pegol), Enbrel® (etanercept), Erelzi® and Benepali® (biosimilars to Enbrel®), SIMPONI® (golimumab), REMICADE® (infliximab), Inflectra® and Flixabi (biosimilars to REMICADE®), Renflexis® (infliximab-abda) and Cosentyx® (secukinumab). Some of these DMARDs may be used for the treatment of ankylosing spondylitis as well as for other immune disorders, such as psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis and others.
AbstractAnkylosing spondylitis (AS) is a form of arthritis, primarily affecting the spine. AS causes an inflammation in vertebrae and can lead to severe chronic pain and significantly decreases the quality of life. In severe cases the disease can lead to ankylosis -- new bone formation in the spine, causing the spine to fuse in a fixed, immobile position. AS can also affect joints and cause inflammation in shoulders, hips, ribs, heels and others. Sometimes the disease may involve even other organs such as eyes (known as iritis or uveitis) or lungs and heart.
Scope2014-2024
Download the full report: https://www.reportbuyer.com/product/5175233
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/us-market-report-for-ankylosing-spondylitis-immunology-drugs-2018---medcore-300556955.html
SOURCE ReportBuyer
